News

Telo Genomics Corp. (TSXV: TELO) announced that John Price will assume the role of Chief Financial Officer effective January 30 , 2026. Price comes with more than 30 years of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets, and holds a B.S. in Accounting from Pennsylvania State University. He...

Full article

AOSL has a track record of exceeding consensus EPS estimates, having outperformed in the last four quarters. With a Zacks Rank of #2 (Buy) and the high ESP, analysts remain bullish on the company’s earnings prospects. The forthcoming February 5 results are expected to confirm a consensus‑EPS beat.

Full article

The Zacks Consensus Estimate has remained unchanged over the last 30 days, indicating that analysts have reassessed initial figures without significant adjustment. However, the Most Accurate Estimate exceeds this consensus, giving AOSL an Earnings Surprise Probability (ESP) of +62.50 %. This positive deviation increases the likelihood that the comp...

Full article

Alpha and Omega Semiconductor (AOSL) is projected to report a year‑over‑year earnings decline when the company releases its December 2025 quarterly results on February 5. Analysts forecast a loss of $0.08 per share, compared with a $0.43 profit in the same period last year, and anticipate revenues of $160 million—a 7.6 % drop from the previous year...

Full article

The company highlighted a robust backlog that should underpin growth in the coming year, and it forecasts historically high turnover for full‑year 2026, with a stronger second‑half contributed by higher shipments and improved execution. CEO Klas Forsström noted that profitability deficits are largely temporary and that the firm has implemented acti...

Full article

Munters Group AB reported a 191 % rise in Q4 order intake, largely driven by a 416 % increase in its Data Center Technologies (DCT) segment while AirTech order intake remained flat. Net sales fell 8 % on currency effects; adjusted EBITA margin slipped due to temporary tariff headwinds in DCT and lower volumes in AirTech. Leverage stood at 2.9×, ref...

Full article

Alvotech has closed a licensing and settlement agreement with Regeneron and Bayer that clears all patent disputes worldwide over its biosimilar to Eylea. The deal gives Alvotech worldwide rights to manufacture and supply the product to global commercial partners—except for the United States, where a separate agreement had already been announced. Un...

Full article

OKYO’s previous phase 2 data showed statistically significant improvements in several endpoints for neuropathic corneal pain patients, reinforcing the potential of urcosimod. The confirmation of the primary endpoint and the alignment on key trial components position the company to advance its novel ocular‑disease–focused pipeline.

Full article

The meeting also validated OKYO Pharma’s Chemistry, Manufacturing and Controls (CMC) strategy and the ocular pain assessment survey (OPAS) used in the protocol. With these elements cleared, the company plans to commence a 120‑patient, multiple‑dose phase 2b/3 study during the first half of 2026.

Full article

BioNTech SE’s shares hovered at $118.00 on January 26, giving the company a trailing P/E of 166.87 and a forward P/E of 7.04. Management signals 2026 will be a transitional year, with a subdued revenue outlook but a potentially pivotal moment for the oncology franchise. The firm holds roughly $17 billion in cash, allowing it to pursue pipeline deve...

Full article